Bionexo Revenue, Valuation, Funding & Investors
Bionexo is valued at $218M as of October 2023. Bionexo revenue was $36M, as disclosed with its October 2021 round.
Last Bionexo valuation
$218M
Undisclosed stage · Oct 2023
Last Bionexo funding round
$20M
Undisclosed stage · Oct 2023
Bionexo revenue
$36M
Undisclosed stage · Oct 2021
Key investors in Bionexo
Bain Capital
Temasek
About Bionexo
Bionexo is a Brazilian digital healthcare platform enabling e-procurement and supply chain management for hospitals and clinics. Founded in 2012 and headquartered in São Paulo, Bionexo connects over 1,000 healthcare providers with 5,000 suppliers through its B2B marketplace for pharmaceuticals, equipment, and services. The ecosystem includes business intelligence dashboards and invoice automation, processing billions in annual transactions across Latin America.
Founded
2000
HQ
São PauloWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Commission, Subscription
Revenue
$36M (Oct 2021)
Valuation
$218M (Oct 2023)
Bionexo Valuation
Bionexo is currently valued at $218M, based on its undisclosed-stage round in October 2023.
The $20M round was led by Bain Capital.
Bionexo's valuation has grown 1.2x from $187M at its undisclosed-stage round in October 2021 to $218M in October 2023, across 2 priced rounds.
Bionexo valuation by funding round
Revenue multiple| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Oct 2023 | Undisclosed stage | $218M | - |
| Oct 2021 | Undisclosed stage | $187M | 5.2x |
Bionexo Revenue
Bionexo's latest recorded revenue is $36M, as of its undisclosed-stage round in October 2021. At a $187M valuation, that implies a 5.2x revenue multiple.
Bionexo revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Oct 2021 | $36M | $187M | 5.2x | Undisclosed stage |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
Bionexo Funding History
Bionexo has raised a total of $126M across 3 funding rounds.
Bionexo's first fundraising round was a $25M undisclosed-stage round in December 2018. The most recent completed round was a $20M undisclosed-stage round in October 2023.
Bionexo funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Oct 2023 | Undisclosed stage | Bain Capital (lead) | $20M | $218M | Bionexo is a Latin American cloud software and data analytics provider connecting healthcare suppliers and providers, offering e-procurement platforms, digital inventory management, revenue cycle management, and analytics solutions. Founded in 2000 in São Paulo, it operates in Brazil, Argentina, Colombia, and Mexico, connecting over 15,000 hospitals, clinics, and suppliers. Its core e-procurement platform facilitates significant transaction volume, expected to exceed R$15 billion in a recent year. In October 2023, Bionexo raised approximately $20 million (Growth Equity - II round) from Bain Capital Tech Opportunities, following a prior R$450 million (~$80-90M USD equivalent) growth investment from the same investor in October 2021. The 2021 round supported expansion of SaaS platforms, M&A, and consolidation in the healthcare sector. a 2021 valuation ranged $202.1-$220M, and an earlier reference notes valuation over R$1 billion at some point. Bain Capital joined existing investors like Prisma Capital, Apus, and Temasek. The investments aim to leverage AI, machine learning, pursue M&A, and drive organic growth in the digitizing Latin American healthcare ecosystem for better efficiency and patient outcomes. Bionexo continues focusing on M&A for expansion in Brazil's healthtech arena as of 2026. Total funding across rounds reaches about $125M with three investors listed. |
| Oct 2021 | Undisclosed stage | Bain Capital (lead) | $81M | $187M | Bionexo is a leading Latin American cloud software and data analytics provider that connects healthcare suppliers and providers, offering digital inventory management, revenue cycle management, analytics solutions, and SaaS platforms to improve efficiency in the digitizing healthcare ecosystem. Founded in 2000, the company has over 500 employees across four countries and integrates technology for healthcare process management. On October 15, 2021, Bain Capital Tech Opportunities made a R$450 million (~US$81.6 million) growth investment in Bionexo, acquiring a 43% stake and becoming the main shareholder while existing investors like Prisma Capital, Apus, and Temasek retained control through founder Mauricio De Lázzari Barbosa's holding. The transaction valued the company at R$1.1 billion post-money, with Bain committing an additional ~US$20 million over two years for further growth. The funds support expansion of healthcare SaaS platforms, AI and machine learning investments, transformational M&A, and consolidation in the sector. Sources confirm the BRL 1.1 billion valuation explicitly tied to this round, with USD equivalents around $199.5-220 million. |
| Dec 2018 | Undisclosed stage | Temasek (lead) | $25M | - | Bionexo is a Brazilian healthcare e-commerce company that received investment from Temasek Holdings. The company operates in the healthcare e-commerce sector in Brazil, positioning itself within the broader digital health and supply chain technology landscape. According to Temasek's 2019 annual review, Bionexo was among new technology and life sciences investments made during the fiscal year ended 31 March 2019. |
Who has invested in Bionexo?
2 investors have backed Bionexo across its funding rounds, including Bain Capital and Temasek.
Lead investors include Bain Capital and Temasek.
Bionexo Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 2 Bionexo investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Bionexo
Bionexo has acquired 6 companies to date.
Last acquisition by Bionexo was on September 16th 2025. Bionexo acquired Overmind for undisclosed valuation.
Latest Acquisitions by Bionexo
| Description | Overmind is a Tel Aviv-headquartered infrastructure monitoring platform that predicts deployment risks from code changes and verifies post-deployment stability. The tool scans Terraform, Kubernetes, and CI/CD pipelines to simulate fallout scenarios, integrating with GitHub, GitLab, and cloud providers like AWS and Azure. Overmind supports DevOps teams at scale by providing real-time alerts and rollback recommendations during infrastructure-as-code updates. | Tradimus is a Brazil-headquartered SaaS platform for health big data and artificial intelligence. Hospitals analyze electronic health records and imaging data for diagnostics and epidemiology studies. The system processes datasets from SUS public health system with predictive models for readmission risks. Tradimus partners with clinics in São Paulo for population health management. | Avatar is a Brazil-based software developer creating specialized applications for the healthcare sector, including WebGLosas electronic health records and commercial simulators. The company delivers web-based tools for medical practice management, patient data handling, and simulation training. Operating from São Paulo, Avatar supports clinics, hospitals, and pharmaceutical firms with scalable digital platforms that streamline workflows and enhance clinical decision-making. | Síntese B2B is a Brazilian software provider specializing in supply chain management platforms for healthcare providers and hospitals. Operating from São Paulo, its Plataforma Síntese automates procurement, inventory tracking, and vendor negotiations through integrated ERP modules compliant with ANVISA regulations. The system connects suppliers of pharmaceuticals, medical devices, and consumables, streamlining bidding processes and reducing costs for public and private health networks across Brazil. | |
| HQ Country |  | | | | |
| HQ City | London | São Paulo | Itu | Recife | |
| Deal Date | 16 Sep 2025 | 12 Sep 2024 | 28 Nov 2022 | 12 Aug 2022 | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Bionexo acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Bionexo Competitors
Bionexo competitors include listed companies like Spok, Infinitt Healthcare and MTI Ltd., and private ones like Buymed, SIRCLO and CodaMetrix.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 Vietnam | Private | - | - | $247M | - | |
 Jakarta | Private | - | - | $343M | - | |
 United States | Publicly listed | $140M | $24M | $217M | 1.5x | |
 South Korea | Publicly listed | $74M | $27M | $219M | - | |
 Japan | Publicly listed | $191M | $38M | $215M | 0.7x | |
| Boston, MA | Private | $48M | - | $220M | 4.6x |
Bionexo Public Comps
Bionexo is still privately-owned, but its public comps include Spok, Infinitt Healthcare, MTI Ltd., Nordhealth, Ascom, Kusurinomadoguchi, Uxin, Giftee, YesAsia and Vente Unique.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $140M | $24M | 1.5x | 1.5x | 8.6x | 7.1x | |||
| $74M | $27M | 0.9x | - | 2.5x | - | |||
| $191M | $38M | 0.7x | 0.7x | 3.7x | 5.6x | |||
| $58M | ($1M) | 3.3x | 3.0x | (163.1x) | 60.5x | |||
| $354M | $39M | 0.6x | 0.5x | 5.1x | 4.7x | |||
| $79M | $26M | 2.4x | 2.2x | 7.0x | 6.5x | |||
| $483M | ($16M) | 1.1x | 0.7x | (34.9x) | (24.7x) | |||
| $90M | $19M | 2.5x | 2.5x | 11.8x | 9.4x | |||
This data is available for Pro users. Sign up to see all Bionexo competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Bionexo
| When was Bionexo founded? | Bionexo was founded in 2000. |
| Where is Bionexo headquartered? | Bionexo is headquartered in São Paulo, Brazil. |
| Is Bionexo publicly listed? | No, Bionexo is a private, VC-backed company. |
| What is Bionexo's valuation? | Bionexo was last valued at $218M in its undisclosed-stage round in October 2023. |
| How much funding has Bionexo raised? | Bionexo has raised $126M across 3 funding rounds. |
| What was Bionexo's last funding round? | Bionexo's last funding round was a $20M undisclosed-stage round in October 2023, led by Bain Capital. |
| Who are Bionexo's investors? | Bionexo's investors include Bain Capital and Temasek. |
| What is Bionexo's revenue? | Bionexo's latest recorded revenue is $36M (October 2021). |
| What is Bionexo's revenue multiple? | Bionexo's latest valuation implies a 5.2x revenue multiple ($187M valuation on $36M of revenue). |
| Which companies are comparable to Bionexo? | Companies comparable to Bionexo include Buymed, SIRCLO, Spok, Infinitt Healthcare, MTI Ltd. and CodaMetrix. |
| How many companies has Bionexo acquired? | Bionexo has acquired 6 companies, including Overmind, Tradimus, Avatar, Síntese B2B and BeeCare. |
See companies similar to Bionexo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.